This submission by MannKind Corp to Diabetes Health was made almost two years ago, and it refers to a two year study using Afrezza as part of that study. I will be interesting to see if any independent news comes at the conclusion of this study from the JDRF.

http://www.diabeteshealth.com/read/2010/08/29/6827/mannkind-corporation-providing-afrezza-to-jdrf-for-artificial-pancreas-project/

Couple that with comments made last year by one of the study leads at JDRF, Dr. Sanjoy Dutta, and you have something else to hang your hat on in the near term. Maybe help start the momentum going in the right direction again.

• Inhaled insulin is the fastest-acting type in clinical development. It reaches the blood stream very quickly, similar to oxygen. Dr. Dutta reports that MannKind’s new inhaled insulin, Afrezza, is performing quite well with type 1 diabetics in clinical studies, and the new delivery system they are testing (improved little inhaler) allows for more specific dosing amounts. This is meal-time insulin only, so patients will still need at least one injection of long-acting insulin. But it is believed that Afrezza could speed up the action of meal-time doses, lowering post-prandial blood sugars.

http://www.diabetesmine.com/2011/05/jdrfs-insulin-initiative-afrezza-roches-diaport-smart-insulin-and-more.html